Zydus Lifesciences (Zydus) and Torrent Pharmaceuticals (Torrent Pharma ) have entered into a Licensing and Supply Agreement to co-market Semaglutide Injection in the Indian market. Under the terms of the agreement, Zydus will manufacture and supply the product, while Torrent Pharma has received semi-exclusive rights to co-market the product in India under its own brand name SEMBOLIC, leveraging its strong presence in chronic therapies and extensive field force across the country. Zydus will market the product under its brand SEMAGLYN, MASHEMA and ALTERME, while Torrent Pharma will market the product under its brand SEMBOLIC. As part of the agreement, Torrent Pharma will pay an upfront licensing fee to Zydus.

Zydus has developed an innovative formulation of Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a reusable patient-friendly pen device, enabling delivery of all strengths for both indications through a single device platform. The formulation combined with the reusable pen device is designed to enhance patient convenience, improve treatment adherence, and support better long-term compliance, addressing key challenges in chronic disease management.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.